Raised $144M across disclosed rounds.[1][6]

Series B closed September 2023, led by OrbiMed.[2][3][7]

post-money valuation is not publicly disclosed.

Named investors include OrbiMed, Fidelity Management & Research Company, NVentures (NVIDIA), Paragon Biosciences, Valor Equity Partners.[2][3][7]

Rama Ranganathan, Co-Founder, Chief Scientist[3][11]

Andrew Ferguson, Co-Founder, Head of Computation[3][11]

Marc Yoskowitz, Chief Executive Officer[6][8][9][10][13][14]

Arjun Rallapalli, Chief Operating Officer[6][8][9][10][13][14]

Gary Krishnan, Chief Scientific Officer[6][8][9][10][13][14]

Uri Herzberg, Chief Drug Discovery Officer[6][8][9][10][13][14]

Csaba Pazmany, Senior Director of Business Development[6][8][9][10][13][14]

Ryan Mork, Senior Director of Data Science[6][8][9][10][13][14]

Genesis Therapeutics · genesistherapeutics.com · Named in the same market context as Evozyne in Pharmaceutical Technology coverage of generative AI drug discovery; both raised Series B rounds in 2023 with NVIDIA participation.[2]

Recursion · recursion.com · Named alongside Evozyne in Endpoints coverage as a life sciences startup touting AI in next-generation drug discovery; NVIDIA invested in both.[3]

Isomorphic Labs · isomorphiclabs.com · Named alongside Evozyne in Endpoints coverage as a comparable AI-driven drug discovery startup competing for the same pharma partnership budgets.[3]

Atomwise · atomwise.com · Named alongside Evozyne in Endpoints coverage as a comparable AI-driven drug discovery startup in the same competitive set.[3]

The customer proof is company-sourced only. No independent source in this ledger confirms it.[8]

Ask for one referenceable production customer.

Not a recommendation. The first thing this ledger cannot answer.

Filled in the side panel for invited readers. This card carries sourced facts only.